LRRC17

Across TCGA pan-cancer cohorts, LRRC17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LRRC17 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LRRC17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC17 expression acts as an unfavorable survival marker.

BLCA, SKCM, and LIHC are the cancer types where LRRC17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.069	0.582	<.001	6	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	5	view →
LIHC	OS	Median	All	0.221	0.690	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LRRC17–BLCA (OS)

Open the BLCA breakdown →